ONdrugDelivery - ONdrugDelivery - drug delivery industry specialised b2b information

#134_2022_June_Recipharm_hero7

CONNECTING PATIENTS AND HEALTHCARE PROVIDERS IN THE AGE OF SELF-ADMINISTERED INJECTABLE DRUGS

Gemma Wood of Bespak by Recipharm explores connected device development trends, the patient-centric benefits the technology has to offer and how, with the help of experienced manufacturing partners connected to key enabling technology partners, they can develop products that deliver improved patient outcomes.

TURNING CONNECTED DRUG DELIVERY PIPE DREAMS INTO REALITY

Mindy Katz discusses the benefits of integrating homecare technologies that are patient centric and connected.

HOW DIGITAL THERAPEUTICS ADD VALUE TO TREATMENTS FOR COMPLEX CONDITIONS

Romain Marmot discusses how external partners with a track record of developing digital therapeutics for numerous chronic conditions and therapies can help life science organisations implement digital solutions across their pipeline, adding value to each therapy while improving medication adherence and clinical outcomes.

MEETING AN UNMET PHARMA NEED: PIONEERING THE WAY TO A CONNECTED FUTURE

Chelsea Williams

MEETING AN UNMET PHARMA NEED: PIONEERING THE WAY TO A CONNECTED FUTURE

Chelsea Williams, Nagisa Kobashi and Nils Weber discuss the digital transformation of injectables, where drug formulation and device are enmeshed within a connected ecosystem powered by patient data.

A PATIENT-CENTRIC, CONNECTED INJECTION DEVICE FOR DECENTRALISED CLINICAL TRIALS – THE HUMAN FACTORS RESULTS ARE IN!

BD (Becton Dickinson & Company)

A PATIENT-CENTRIC, CONNECTED INJECTION DEVICE FOR DECENTRALISED CLINICAL TRIALS – THE HUMAN FACTORS RESULTS ARE IN!

Aurélie Pager and Mircea Despa follow up on an article published in the December 2021 issue of ONdrugDelivery. BD has now completed a human factors study assessing the usability, acceptance and ease of use of its connected injection prototype for clinical trials.

PAVING THE WAY TO INTEGRATED DEVICE-DIGITAL SOLUTIONS

Dr Andreas Schneider

PAVING THE WAY TO INTEGRATED DEVICE-DIGITAL SOLUTIONS

Andreas Schneider and Philippe Müller discuss the potential benefits and challenges of implementing connected device-digital solutions within the healthcare sector to improve the treatment of chronic conditions.

FOCUS ON ADHERENCE TO EMBRACE DCT BENEFITS

Dr Bernard Vrijens

FOCUS ON ADHERENCE TO EMBRACE DCT BENEFITS

Bernard Vrijens looks at the effect of decentralised clinical trials on medication adherence in clinical studies.

A GAME CHANGER FOR HIGH-RISK MEDICATIONS VIA AN INTRANASAL DELIVERY PLATFORM

A GAME CHANGER FOR HIGH-RISK MEDICATIONS VIA AN INTRANASAL DELIVERY PLATFORM

Marcel Botha, Andreas Bilstein, Houssam Elghobary and Rouven Kraus discuss the benefits of the Validose digital health platform for the safe delivery of high-value and/or high-risk products.

THE SMART INHALER REVOLUTION: ARE WE THERE YET?

Cambridge Design Partnership

THE SMART INHALER REVOLUTION: ARE WE THERE YET?

Mark Allen, David Blakey and Karla Sanchez discuss the benefits of smart inhalers and how they could influence the commercialisation of respiratory drugs in the future.

HOW DIGITAL UX IN CLINICAL TRIALS CAN IMPROVE MEASURES

HOW DIGITAL UX IN CLINICAL TRIALS CAN IMPROVE MEASURES

Ben Cox discusses the key challenges, principles and advantages of following a user-experience approach to digital health technologies in clinical trials.

HOW RECENT NFC ADVANCES ENABLE ANTI-COUNTERFEIT DRUG CONTAINMENT & SUPPORT ADHERENCE

HOW RECENT NFC ADVANCES ENABLE ANTI-COUNTERFEIT DRUG CONTAINMENT & SUPPORT ADHERENCE

Sylvia Kaiser-Kershaw discusses how recent near-field communication tagging advancements can enable pharmaceutical companies to protect the authenticity and integrity of their products, while also making it easier for healthcare professionals and patients to use medications more effectively through intelligent drug delivery systems.

NO TYPE: AN APP TO PREDICT PATIENTS’ LIKELIHOOD TO TAKE MEDICATION AS PRESCRIBED

NO TYPE: AN APP TO PREDICT PATIENTS’ LIKELIHOOD TO TAKE MEDICATION AS PRESCRIBED

Louisa Harvey, Alper Hulusi, Bjarki Holm and Stefan Olafsson introduce their quick and accessible app for identifying whether or not a patient is likely to take their medication as prescribed.

CYBERSECURITY AND THE CHALLENGES OF CLOUD CONNECTIVITY

Gabrielle Whitworth-Smith

CYBERSECURITY AND THE CHALLENGES OF CLOUD CONNECTIVITY

Gabrielle Whitworth-Smith and Thomas Watts look at the benefits and risks associated with cloud connectivity and the accompanying cybersecurity challenges.

CONNECTIVITY IN HEALTHCARE – FROM THE MILLENNIUM TO THE PANDEMIC AND BEYOND

Napoleon Monroe

CONNECTIVITY IN HEALTHCARE – FROM THE MILLENNIUM TO THE PANDEMIC AND BEYOND

Napoleon Monroe looks back at the factors that influenced the underwhelming uptake of connectivity-enabling technologies in the healthcare sector over the first two decades of the 21st century, how the covid-19 pandemic changed everything and what current healthcare challenges connectivity might solve.

SUPPORTING PATIENTS ON THE ROAD TO SELF-CARE

SUPPORTING PATIENTS ON THE ROAD TO SELF-CARE

Michael Earl discusses the importance of transitioning current healthcare models to embrace patient self-management and how advanced drug delivery device technologies, such as connectivity, can ease this burden on overstretched healthcare services.

SMART DRUG DELIVERY DEVICES IMPROVE MEDICATION ADHERENCE: HERE’S HOW

SMART DRUG DELIVERY DEVICES IMPROVE MEDICATION ADHERENCE: HERE’S HOW

Paul Edalat and Mehdi Hatamian take an in-depth look at medication non-adherence and how technology can be used to improve compliance rates and optimise patient outcomes.

PUTTING PROCESS ENGINEERING INTO ACTION

Jonathan Kearns

PUTTING PROCESS ENGINEERING INTO ACTION

Jonathan Kearns and Kevin Huang consider how engineering competencies are being driven to the next level by leveraging process engineering and how this can transform drug-device projects.

PREMIUMCOAT<sup>®</sup> SOLUTIONS: HELPING CONTROL THE LEVEL OF SILICONE TO PROTECT SENSITIVE THERAPEUTICS

PREFILLED SYRINGES

Sebastien Cordier

PREMIUMCOAT^® SOLUTIONS: HELPING CONTROL THE LEVEL OF SILICONE TO PROTECT SENSITIVE THERAPEUTICS

Sébastien Cordier, Vincent Holterboch and Estelle Verger discuss how coated elastomer components, such as Aptar Pharma’s PremiumCoat^®, can help drug developers optimise the balance between component processability and minimising silicone migration into a drug product.

INJECTING THE FUTURE

INJECTING THE FUTURE

Simone Farina discusses Flex’s new smart autoinjector platform for the healthcare market, designed to enable original equipment manufacturers to accelerate time-to-market, reduce costs and boost reliability, while ensuring patient compliance.

CONNECTED DRUG DELIVERY – MAXIMISING ACCESS BY DESIGN

Jabil Healthcare

CONNECTED DRUG DELIVERY – MAXIMISING ACCESS BY DESIGN

Oliver Eden discusses the factors that drive the design and development of a reusable autoinjector solution. Foremost amongst these considerations is the patient, in terms of ease of use with the device itself and maximising access to the broadest possible population with a versatile, portfolio-enabling platform ready for the connected world.

ADVANCEMENTS AND EVOLUTION OF POWER SOURCES IN DRUG DELIVERY

ADVANCEMENTS AND EVOLUTION OF POWER SOURCES IN DRUG DELIVERY

William Welch considers the evolution of compressed gas alternatives to spring power for single-use drug delivery devices.

A CHECKLIST FOR AUTOINJECTOR DESIGN

A CHECKLIST FOR AUTOINJECTOR DESIGN

Michael Earl outlines the five key questions autoinjector designers typically ask during the development process and the choices available for tailoring autoinjector products.

EXCELLENCE THROUGH SIMPLICITY: PICCOJECT™ AUTOINJECTOR PLATFORM

Dr Fred Metzmann

EXCELLENCE THROUGH SIMPLICITY: PICCOJECT™ AUTOINJECTOR PLATFORM

Fred Metzmann and Chris Muenzer discuss the simplicity of the PiccoJect™ autoinjector platform and the company's commitment to sustainability.

Technology Showcase: CCBio’s Felice Dose

Technology Showcase: CCBio’s Felice Dose

CCBio introduces its wearable (on-body) injector, Felice Dose, which is capable of handling various drug volumes, concentrations and viscosities, as well as different injection speeds and delivery times.

OXYCAPT™: A SUPERIOR PRIMARY CONTAINER MATERIAL FOR BIOLOGICS AND GENE AND CELL THERAPIES

PREFILLED SYRINGES

Hiroki Hasegawa

Mitsubishi Gas Chemical

OXYCAPT™: A SUPERIOR PRIMARY CONTAINER MATERIAL FOR BIOLOGICS AND GENE AND CELL THERAPIES

Hiroki Hasegawa and Tomohiro Suzuki provide an overview of the OXYCAPT multilayer vial and syringe, along with a discussion of how OXYCAPT fares at low and very low temperatures.

XERIJECT™: NON-AQUEOUS FORMULATIONS FOR SC INJECTION OF ULTRA-HIGH-CONCENTRATION BIOLOGICS

Dr Steven Prestrelski

Xeris Pharmaceuticals

XERIJECT™: NON-AQUEOUS FORMULATIONS FOR SC INJECTION OF ULTRA-HIGH-CONCENTRATION BIOLOGICS

Steven Prestrelski introduces the XeriJect non-aqueous formulation technology that creates formulations with visco-elastic properties, opening the door to subcutaneous injection of difficult-to-formulate biologics, such as monoclonal antibodies, at very high concentrations.

EXTRACELLULAR VESICLE ENGINEERING: OPTIMISING NATURE’S NON-IMMUNOGENIC, DRUG DELIVERY PLATFORM

Dr Anna Cifuentes-Rius

EXTRACELLULAR VESICLE ENGINEERING: OPTIMISING NATURE’S NON-IMMUNOGENIC, DRUG DELIVERY PLATFORM

Anna Cifuentes-Rius discusses the exciting potential of extracellular vesicles to advance drug delivery, in particular their natural ability to carry API payloads across difficult-to-traverse biological barriers.

ENABLING A NEW PARADIGM FOR PEPTIDE DRUG DEVELOPMENT

Xeris Pharmaceuticals

ENABLING A NEW PARADIGM FOR PEPTIDE DRUG DEVELOPMENT

Michael Neely reviews peptide formulations and introduces Xeris's XeriSol™ technology and its potential paradigm-changing capabilities.

RECENT TRENDS & DEVELOPMENTS IN INJECTABLE FORMULATION & DELIVERY

Dr Martin Gonzalez

RECENT TRENDS & DEVELOPMENTS IN INJECTABLE FORMULATION & DELIVERY

Martin Gonzalez details current trends in sterile injectable formulations and their delivery devices, and the challenges pharma and its contract development and manufacturing company partners face in bringing emerging breakthroughs to market.

INTERVIEW: STEVEN KAUFMAN, STEVANATO GROUP, & MICHAEL EARL, OWEN MUMFORD

Stevanato Group

INTERVIEW: STEVEN KAUFMAN, STEVANATO GROUP, & MICHAEL EARL, OWEN MUMFORD

In this exclusive interview, Steven Kaufman of Stevanato Group, and Michael Earl of Owen Mumford, talked with us about their companies' recent major agreement for the manufacturing and provision of prefillable syringes for the advanced two-step, single-use autoinjector, Aidaptus^®.

INTERVIEW: AURELIO ARIAS, IQVIA

INTERVIEW: AURELIO ARIAS, IQVIA

Aurelio Arias of IQVIA discusses trends in the drug delivery industry, including how device and packaging manufacturers are increasingly aligning as strategic partners to speed innovation and reduce reliance on pharma investment.

ARE GOVERNMENTS BANNING THE MOST ENVIRONMENTALLY FRIENDLY INHALER?

ARE GOVERNMENTS BANNING THE MOST ENVIRONMENTALLY FRIENDLY INHALER?

Rob Udale, Catriona Eldridge and Omar Shah assess the assertion that pMDIs are the most environmentally damaging of the available pulmonary drug delivery device archetypes, and explore some of the intricacies not accounted for in the public discourse surrounding pMDIs.

SUSTAINABILITY: WHAT CAN THE HEALTHCARE SECTOR LEARN FROM CONSUMER DESIGN?

Cambridge Design Partnership

SUSTAINABILITY: WHAT CAN THE HEALTHCARE SECTOR LEARN FROM CONSUMER DESIGN?

Fran Penrose considers the lessons the healthcare sector can draw from the fast-moving consumer sector when designing for sustainability and asks, “Can we go even further?”

SUSTAINABILITY IN MEDTECH DEVELOPMENT: AN ITERATIVE APPROACH BASED ON ECODESIGN AND LIFE CYCLE SCREENINGS

Christoffer Thomsen

SUSTAINABILITY IN MEDTECH DEVELOPMENT: AN ITERATIVE APPROACH BASED ON ECODESIGN AND LIFE CYCLE SCREENINGS

Life Cycle Assessments are a valuable but time-consuming and, ultimately, retrospective method for assessing MedTech product sustainability. Christoffer Thomsen and Peter Werner Hansen dive into an iterative and data-driven approach to more sustainable MedTech development based on Ecodesign and Life Cycle Screenings.

SMART SOLUTIONS TO REDUCE CARBON FOOTPRINT

SMART SOLUTIONS TO REDUCE CARBON FOOTPRINT

Rob Doorakkers and Geert van Amstel discuss why the company decided to become carbon neutral, how it is working to make injection moulding more sustainable and how the organisation is minimising its impact on the environment.

DESIGNING DRUG DELIVERY DEVICES TO MEET EMERGING NEEDS AND SUSTAINABILITY GOALS

Dr Pierre Moulinie

DESIGNING DRUG DELIVERY DEVICES TO MEET EMERGING NEEDS AND SUSTAINABILITY GOALS

Pierre Moulinié, Isaac Platte and Lauren Zetts discuss how polycarbonate-based materials deliver value to emerging drug delivery devices.

HOW CAN THE PHARMA INDUSTRY PREPARE FOR NEW pMDI PROPELLANTS?

HOW CAN THE PHARMA INDUSTRY PREPARE FOR NEW pMDI PROPELLANTS?

Nick Atkinson looks at the changes that are set to hit pressurised metered dose inhaler manufacturing as new propellants are introduced and how pharma companies can prepare for the switch.

CAPSULES: CLASSIC DRUG DELIVERY FORM HOLDS POTENTIAL FOR SUSTAINABLE DELIVERY

Dr Jnanadeva Bhat

CAPSULES: CLASSIC DRUG DELIVERY FORM HOLDS POTENTIAL FOR SUSTAINABLE DELIVERY

Jnanadeva Bhat and Anita Solanki discuss the role that hard capsules are able to play in delivering a more sustainable pharmaceutical industry, both as an oral solid dosage form and in dry powder inhalers.

SUSTAINABILITY CONSIDERATIONS FOR END-TO-END DRUG DELIVERY DEVICE SOLUTIONS

SUSTAINABILITY CONSIDERATIONS FOR END-TO-END DRUG DELIVERY DEVICE SOLUTIONS

Barbara Lead outlines the sustainability efforts undertaken by SMC Group associated companies, including facilitating the transition from hospital to at-home treatment and investment in greener facilities.

1
2
3
…
30
Next

See what ondrugdelivery's readers and contributors think

Li-Chun Tsou, PhD, MBA
Principal Engineer
Merck & Co

Your website and publication is a great asset for me. I’d recommend your publication to my colleagues. I am sure that we will gain knowledge and update information through your timely report. Thanks for making it available.

Abby Lockwood
Consultant
Plan Strategic

ONdrugDelivery Magazine is a great resource that brings a lot of value to the work my team and I are doing in the area of drug delivery. The device-specific content as well as the broader discussions surrounding industry trends and issues are extremely informative and very well written.

Donna Bibber
President
Micro Engineering Solutions

I picked up your latest copy at the Boston PODD event and read it with great interest. You’ve really come a long way and you put out an amazingly professional and value-packed magazine.

Dr Cristian Vilos

I‘m working on the development of microparticles for the release of veterinary antibiotics, and polymeric nanoparticles for siRNA and chemotherapeutic delivery. ONdrugDelivery has been a very usefull platform to connect the scientific research, and marketed drug development.

Top